There are currently 474 clinical trials in Kansas City, Kansas looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Kansas Medical Center, University of Kansas Cancer Center, Kansas University Medical Center and Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Phase II Study of Lonsurf (TAS-102) in Metastatic Platinum and Checkpoint Inhibitor-resistant Bladder Cancer
Recruiting
This study evaluates the clinical benefit of TAS-102 in participants with metastatic urothelial carcinoma who are resistant to cisplatin or carboplatin front-line and checkpoint inhibitors as second line therapy. All participants will receive TAS-102 in oral form twice per day on Days 1-5 and Days 8-12 of each 28 day cycle.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/09/2022
Locations: University of Kansas Cancer Center, Westwood Campus, Kansas City, Kansas
Conditions: Bladder Cancer
MultiStem® Administration for Stroke Treatment and Enhanced Recovery Study
Recruiting
A Phase 3 study to examine the safety and effectiveness of the allogeneic, adult stem cell investigational product, MultiStem, in adults who have suffered an acute ischemic stroke in the previous 18-36 hours.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/08/2022
Locations: Athersys Investigational Site 119, Kansas City, Kansas
Conditions: Ischemic Stroke
Natural History of COVID-19-Related Atrial Fibrillation
Recruiting
The unCOVer-AF prospective, multicenter registry aims at determining the natural history of atrial fibrillation (AF) via continuous cardiac rhythm monitoring in patients with a first arrhythmic episode during COVID-19 hospitalization.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/15/2021
Locations: Kansas City Heart Rhythm Institute, Overland Park, Kansas City, Kansas
Conditions: COVID-19, Atrial Fibrillation New Onset
Function of Circulating Exosomes in Sepsis-induced Immunosuppression
Recruiting
This is a single-center prospective bio-specimen analysis and observational study aiming to define immune pathways disrupted in bacterial sepsis and to identify clinically useful biomarkers of immune status.
Gender:
All
Ages:
50 years and above
Trial Updated:
07/16/2021
Locations: University of Kansas Medical Center, Kansas City, Kansas
Conditions: Sepsis, Septic Shock, Sepsis Syndrome, Sepsis Bacterial, Sepsis, Severe, Sepsis Bacteremia
Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML
Recruiting
This is a randomized, multi-center, double-blind, placebo-controlled study designed to evaluate the efficacy of crenolanib administered following salvage chemotherapy, consolidation chemotherapy, post bone marrow transplantation and as maintenance in relapsed/refractory AML subjects with FLT3 activating mutation.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/28/2021
Locations: Kansas University, Kansas City, Kansas
Conditions: Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations
Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML
Recruiting
A phase III randomized multi-center study designed to compare the efficacy of crenolanib with that of midostaurin when administered following induction chemotherapy, consolidation chemotherapy and bone marrow transplantation in newly diagnosed AML subjects with FLT3 mutation. About 510 subjects will be randomized in a 1:1 ratio to receive either crenolanib in addition to standard first line treatment of AML (chemotherapy and if eligible, transplantation) (arm A) or midostaurin and standard treat... Read More
Gender:
All
Ages:
Between 18 years and 60 years
Trial Updated:
05/21/2020
Locations: University of Kansas, Kansas City, Kansas
Conditions: Newly Diagnosed FLT3 Mutated AML